Therapeutic Response

v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Papillary Thyroid Cancer.

Statements

Source and description
Retevmo (selpercatinib) [product monograph]. HC. Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.